Literature DB >> 16011537

BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005.

A L Pozniak1, R F Miller, M C I Lipman, A R Freedman, L P Ormerod, M A Johnson, S Collins, S B Lucas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16011537     DOI： 10.1111/j.1468-1293.2005.00293.x

Source DB:  PubMed          Journal:  HIV Med        ISSN： 1464-2662            Impact factor:   3.180


× No keyword cloud information.
  14 in total

1.  Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers.

Authors:  Awewura Kwara; Karen T Tashima; Julie B Dumond; Pamela Poethke; Jaclyn Kurpewski; Angela D M Kashuba; Michael H Court; David J Greenblatt
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

2.  Progressive symptoms and signs following institution of highly active antiretroviral therapy and subsequent antituberculosis therapy: immune reconstitution syndrome or infection?

Authors:  R F Miller; M Shahmanesh; M D Talbot; M J Wiselka; P J Shaw; C Bacon; C M Robertson
Journal:  Sex Transm Infect       Date:  2006-04       Impact factor: 3.519

3.  Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.

Authors:  Chonlaphat Sukasem; Tim R Cressey; Pattamawan Prapaithong; Yardpiroon Tawon; Ekawat Pasomsub; Chutatip Srichunrusami; Thawinee Jantararoungtong; Marc Lallement; Wasun Chantratita
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

Review 4.  Tuberculosis and HIV co-infection: a practical therapeutic approach.

Authors:  Ronan A M Breen; Leonie Swaden; Jayne Ballinger; Marc C I Lipman
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  The growing impact of HIV infection on the epidemiology of tuberculosis in England and Wales: 1999 2003.

Authors:  Aliko B Ahmed; Ibrahim Abubakar; Valerie Delpech; Marc Lipman; Delia Boccia; Josh Forde; Delphine Antoine; John M Watson
Journal:  Thorax       Date:  2007-02-20       Impact factor: 9.139

6.  In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.

Authors:  Dinko Rekić; Daniel Röshammar; Jackson Mukonzo; Michael Ashton
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

7.  CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.

Authors:  Awewura Kwara; Margaret Lartey; Kwamena W C Sagoe; Ernest Kenu; Michael H Court
Journal:  AIDS       Date:  2009-10-23       Impact factor: 4.177

Review 8.  Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.

Authors:  Awewura Kwara; Geetha Ramachandran; Soumya Swaminathan
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-01       Impact factor: 4.481

9.  CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.

Authors:  Awewura Kwara; Margaret Lartey; Kwamena W Sagoe; Naser L Rzek; Michael H Court
Journal:  Br J Clin Pharmacol       Date:  2009-04       Impact factor: 4.335

10.  Factors influencing lopinavir and atazanavir plasma concentration.

Authors:  Wolfgang Stöhr; David Back; David Dunn; Caroline Sabin; Alan Winston; Richard Gilson; Deenan Pillay; Teresa Hill; Jonathan Ainsworth; Brian Gazzard; Clifford Leen; Loveleen Bansi; Martin Fisher; Chloe Orkin; Jane Anderson; Margaret Johnson; Philippa Easterbrook; Sara Gibbons; Saye Khoo
Journal:  J Antimicrob Chemother       Date:  2010-01       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.